Login to Your Account



Vitae, GSK Enter Collaboration To Develop Renin Inhibitors

By Randall Osborne


Tuesday, June 21, 2005
Talk about making the pulse race: Privately held Vitae Pharmaceuticals Inc., with its renin inhibitor program still in the preclinical stage, nailed down a potential $175 million deal with GlaxoSmithKline plc to develop drugs for hypertension and related cardiovascular disorders. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription